Walder Wyss advises Perconex Holding in the acquisition of Flex Suisse, an alternative legal service provider in Switzerland and Liechtenstein. The merger creates a talent pool of over 3,000 lawyers, covering three countries with contacts in
Tags :Alexander Gutmans
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Private investment company Drs Investment sells 100 per cent of the shares in the Swiss software company Xelog to Prologistik Holding. The acquisition of Xelog, the Swiss logistics software specialist, is part of Prologistik’s strategy
Walder Wyss acted as legal counsel to Alentis Therapeutics on the USD 67 million series B financing round. Morningside Venture Investments led the financing, joined by Jeito Capital and Series A investors Biomed Partners, BB Pureos
Oculis has closed an oversubscribed USD 57m Series C financing round. It was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay
Walder Wyss advised the shareholders of HUBERLAB.AG on the sale to Calibre Scientific. The team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured) and included Robert Desax (Partner,
Walder Wyss advises Boehringer Ingelheim. The team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured left) and Robert von Rosen (Partner, Corporate/M&A and Venture Capital). VISCHER advised
VISCHER is advising Noema Pharma in this transaction. The team is led by Matthias Staehelin (Corporate, pictured left). Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors. The team included
The team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured), Robert von Rosen (Partner, Corporate/M&A and Venture Capital) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).
Homburger advises VectivBio on USD 110 m crossover financing.The team was led by partner Andreas Müller (pictured left). Walder Wyss advised BPI France, Cowen Healthcare Investments, Novo Ventures, OrbiMed and Versant Ventures as lead